Jordi Barretina 1 , 2 , 3 , Giordano Caponigro 4 , Nicolas Stransky 1 , Kavitha Venkatesan 4 , Adam A. Margolin 1 , Sungjoon Kim 5 , Christopher J. Wilson 4 , Joseph Lehár 4 , Gregory V. Kryukov 1 , Dmitriy Sonkin 4 , Anupama Reddy 4 , Manway Liu 4 , Lauren Murray 1 , Michael F. Berger 1 , John E. Monahan 4 , Paula Morais 1 , Jodi Meltzer 4 , Adam Korejwa 1 , Judit Jané-Valbuena 1 , 2 , Felipa A. Mapa 4 , Joseph Thibault 5 , Eva Bric-Furlong 4 , Pichai Raman 4 , Aaron Shipway 5 , Ingo H. Engels 5 , Jill Cheng 6 , Guoying K. Yu 6 , Jianjun Yu 6 , Peter Aspesi Jr. 4 , Melanie de Silva 4 , Kalpana Jagtap 4 , Michael D. Jones 4 , Li Wang 4 , Charles Hatton 3 , Emanuele Palescandolo 3 , Supriya Gupta 1 , Scott Mahan 1 , Carrie Sougnez 1 , Robert C. Onofrio 1 , Ted Liefeld 1 , Laura MacConaill 3 , Wendy Winckler 1 , Michael Reich 1 , Nanxin Li 5 , Jill P. Mesirov 1 , Stacey B. Gabriel 1 , Gad Getz 1 , Kristin Ardlie 1 , Vivien Chan 6 , Vic E. Myer 4 , Barbara L. Weber 4 , Jeff Porter 4 , Markus Warmuth 4 , Peter Finan 4 , Jennifer L. Harris 5 , Matthew Meyerson 1 , 2 , 3 , Todd R. Golub 1 , 3 , 7 , 8 , Michael P. Morrissey 4 , William R. Sellers 4 , Robert Schlegel 4 , Levi A. Garraway 1 , 2 , 3
28 March 2012
The systematic translation of cancer genomic data into knowledge of tumor biology and therapeutic avenues remains challenging. Such efforts should be greatly aided by robust preclinical model systems that reflect the genomic diversity of human cancers and for which detailed genetic and pharmacologic annotation is available 1 . Here we describe the Cancer Cell Line Encyclopedia (CCLE): a compilation of gene expression, chromosomal copy number, and massively parallel sequencing data from 947 human cancer cell lines. When coupled with pharmacologic profiles for 24 anticancer drugs across 479 of the lines, this collection allowed identification of genetic, lineage, and gene expression-based predictors of drug sensitivity. In addition to known predictors, we found that plasma cell lineage correlated with sensitivity to IGF1 receptor inhibitors; AHR expression was associated with MEK inhibitor efficacy in NRAS-mutant lines; and SLFN11 expression predicted sensitivity to topoisomerase inhibitors. Altogether, our results suggest that large, annotated cell line collections may help to enable preclinical stratification schemata for anticancer agents. The generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of “personalized” therapeutic regimens 2 .